Plasma Cell Myeloma Type Posttransplant Lymphoproliferative Disorder in an 18-Month-Old Heart Transplant Recipient Case Report and Review of the LiteratureXue, Lijun MD, PhD*; Zuppan, Craig MD*; Wang, Tiannan MD, PhD*; Kheradpour, Albert MD†; Rowsell, Edward H. MD, PhD*; Wang, Jun MD*Journal of Pediatric Hematology/Oncology: May 13, 2019 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/MPH.0000000000001510 Clinical and Laboratory Observations: PDF Only Buy PAP Abstract Author InformationAuthors Article MetricsMetrics Plasma cell myeloma type posttransplant lymphoproliferative disorder (PTLD) is a rare subtype of monomorphic B-cell/plasmacytic-type PTLD. Only 10 cases of monomorphic plasmacytic-type PTLD have been previously reported in pediatric transplant recipients (kidney, liver, small bowel-liver, and heart). We present a case of Epstein-Barr virus positive monomorphic plasma cell myeloma type PTLD that developed 10 months after cardiac transplant in an 18-month-old boy. The bone marrow showed replacement by about 20% to 40% lambda-restricted plasmacytoid lymphocytes and plasma cells (by immunohistochemistry and flow cytometry, respectively). His serum free lambda to kappa light chain ratio was >300, comparable to that seen in myeloma in nontransplant patients. The neoplastic cells were Epstein-Barr virus small RNA positive by in situ hybridization. He was treated with rituximab in combination with ganciclovir, intravenous immune globulin, and discontinuation of immunosuppressants. However, he succumbed to septic shock and multiorgan failure 1 month after diagnosis. *Department of Pathology and Laboratory Medicine, Loma Linda University Medical Center †Department of Pediatric Hematology and Oncology, Loma Linda University Children Hospital, Loma Linda, CA The authors declare no conflict of interest. Reprints: Jun Wang, MD, Department of Pathology and Laboratory Medicine, 11234 Anderson Street, Room 2151, Loma Linda, CA 92354 (e-mail: firstname.lastname@example.org). Received July 11, 2018 Accepted April 10, 2019 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.